Securing continuing appropriations for ovarian cancer research and awareness programs at CDC, NIH, and DoD.
Supporting legislation to improve access and care for ovarian cancer patients including:
S 765/HR 1526 Reducing Hereditary Cancer Act
S 642 Finn Sawyer Access to Cancer Testing Act
Coverage for multi-cancer early diagnosis legislation
Johanna's Law Modernization and Reauthorization Act
Duration: January 14, 2016
to
present
General Issues: Budget/Appropriations , Health Issues
Spending: about $0 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2016: U.S. Senate, House of Representatives, Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Ovarian Cancer Research Fund Alliance had in-house lobbyists. The report was filed on May 7.
Original Filing: 301578535.xml
Lobbying Issues
Securing continuing appropriations for ovarian cancer research and awareness programs at CDC, NIH, and DoD.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Supporting legislation to improve access and care for ovarian cancer patients including:
S 765/HR 1526 Reducing Hereditary Cancer Act
S 642 Finn Sawyer Access to Cancer Testing Act
Coverage for multi-cancer early diagnosis legislation
Johanna's Law Modernization and Reauthorization Act
Agencies Lobbied
U.S. Senate
4th Quarter, 2023
In Q4, Ovarian Cancer Research Fund Alliance had in-house lobbyists. The report was filed on Feb. 5.
Original Filing: 301543059.xml
Lobbying Issues
Securing continuing appropriations for ovarian cancer research and awareness programs at CDC, NIH, and DoD.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Supporting legislation to improve access and care for ovarian cancer patients including:
S 765/HR 1526 Reducing Hereditary Cancer Act
S 642 Finn Sawyer Access to Cancer Testing Act
Coverage for multi-cancer early diagnosis legislation
Johanna's Law Modernization and Reauthorization Act
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, Ovarian Cancer Research Fund Alliance had in-house lobbyists. The report was filed on Nov. 20, 2023.
Original Filing: 301519209.xml
Lobbying Issues
Securing continuing appropriations for ovarian cancer research and awareness programs at CDC, NIH, and DoD.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Supporting legislation to improve access and care for ovarian cancer patients including:
S 765/HR 1526 Reducing Hereditary Cancer Act
S 642 Finn Sawyer Access to Cancer Testing Act
Coverage for multi-cancer early diagnosis legislation
Johanna's Law Modernization and Reauthorization Act
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, Ovarian Cancer Research Fund Alliance had in-house lobbyists. The report was filed on Aug. 28, 2023.
Original Filing: 301495544.xml
Lobbying Issues
Securing continuing appropriations for ovarian cancer research and awareness programs at CDC, NIH, and DoD.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Supporting legislation to improve access and care for ovarian cancer patients including:
S 765/HR 1526 Reducing Hereditary Cancer Act
S 642 Finn Sawyer Access to Cancer Testing Act
Coverage for multi-cancer early diagnosis legislation
Johanna's Law Modernization and Reauthorization Act
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, Ovarian Cancer Research Fund Alliance had in-house lobbyists. The report was filed on May 30, 2023.
Original Filing: 301471547.xml
Lobbying Issues
Securing continuing appropriations for ovarian cancer research and awareness programs at CDC, NIH, and DoD.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Supporting legislation to improve access and care for ovarian cancer patients including:
S 765/HR 1526 Reducing Hereditary Cancer Act
S 642 Finn Sawyer Access to Cancer Testing Act
Coverage for multi-cancer early diagnosis legislation
Johanna's Law Modernization and Reauthorization Act
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, Ovarian Cancer Research Fund Alliance had in-house lobbyists. The report was filed on Feb. 6, 2023.
Original Filing: 301445763.xml
Lobbying Issues
Supporting ongoing appropriations for ovarian cancer related programs within NCI, CDC and DoD.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Supporting HR 1946 to provide coverage for a multi-cancer screening diagnostic when it is FDA-approved.
Supporting S. 1612 and S. 368 to improve telehealth medicine.
Supporting HR 4412 to reauthorize Johanna's Law.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, Ovarian Cancer Research Fund Alliance had in-house lobbyists. The report was filed on Nov. 2, 2022.
Original Filing: 301421693.xml
Lobbying Issues
Supporting ongoing appropriations for ovarian cancer related programs within NCI, CDC and DoD.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Supporting HR 1946 to provide coverage for a multi-cancer screening diagnostic when it is FDA-approved.
Supporting S. 1612 and S. 368 to improve telehealth medicine.
Supporting HR 4412 to reauthorize Johanna's Law.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, Ovarian Cancer Research Fund Alliance had in-house lobbyists. The report was filed on Aug. 23, 2022.
Original Filing: 301399224.xml
Lobbying Issues
Supporting ongoing appropriations for ovarian cancer related programs within NCI, CDC and DoD.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Supporting HR 1946 to provide coverage for a multi-cancer screening diagnostic when it is FDA-approved.
Supporting S. 1612 and S. 368 to improve telehealth medicine.
Supporting HR 4412 to reauthorize Johanna's Law.
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, Ovarian Cancer Research Fund Alliance had in-house lobbyists. The report was filed on May 24, 2022.
Original Filing: 301375369.xml
Lobbying Issues
Supporting ongoing appropriations for ovarian cancer related programs within NCI, CDC and DoD.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Supporting HR 1946 to provide coverage for a multi-cancer screening diagnostic when it is FDA-approved.
Supporting S. 1612 and S. 368 to improve telehealth medicine.
Supporting HR 4412 to reauthorize Johanna's Law.
Agencies Lobbied
U.S. Senate
4th Quarter, 2021
In Q4, Ovarian Cancer Research Fund Alliance had in-house lobbyists. The report was filed on Feb. 9, 2022.
Original Filing: 301340888.xml
Lobbying Issues
Supporting ongoing appropriations for ovarian cancer related programs within NCI, CDC and DoD.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Supporting HR 1946 to provide coverage for a multi-cancer screening diagnostic when it is FDA-approved.
Supporting S. 1612 and S. 368 to improve telehealth medicine.
Supporting HR 4412 to reauthorize Johanna's Law.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
In Q3, Ovarian Cancer Research Fund Alliance had in-house lobbyists. The report was filed on Dec. 22, 2021.
Original Filing: 301319377.xml
Lobbying Issues
Supporting ongoing appropriations for ovarian cancer related programs within NCI, CDC and DoD.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Supporting HR 1946 to provide coverage for a multi-cancer screening diagnostic when it is FDA-approved.
Supporting S. 1612 and S. 368 to improve telehealth medicine.
Supporting HR 4412 to reauthorize Johanna's Law.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2021
In Q2, Ovarian Cancer Research Fund Alliance had in-house lobbyists. The report was filed on Sept. 24, 2021.
Original Filing: 301295732.xml
Lobbying Issues
Supporting ongoing appropriations for ovarian cancer related programs within NCI, CDC and DoD.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Supporting HR 1946 to provide coverage for a multi-cancer screening diagnostic when it is FDA-approved.
Supporting S. 1612 and S. 368 to improve telehealth medicine.
Supporting HR 4412 to reauthorize Johanna's Law.
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, Ovarian Cancer Research Fund Alliance had in-house lobbyists. The report was filed on May 3, 2021.
Original Filing: 301270108.xml
Lobbying Issues
Supporting ongoing appropriations for ovarian cancer related programs within NCI, CDC and DoD.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Supporting HR 1946 to provide coverage for a multi-cancer screening diagnostic when it is FDA-approved.
Supporting S. 1612 and S. 368 to improve telehealth medicine.
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, Ovarian Cancer Research Fund Alliance had in-house lobbyists. The report was filed on Feb. 16, 2021.
Original Filing: 301248486.xml
Lobbying Issues
Supporting passage of ongoing appropriations for DoD's OCRP within the CDMRP.
Supporting passage of ongoing appropriations for CDC's Johanna's Law and Ovarian Cancer Control Initiative.
Supporting passage of ongoing appropriations for NCI.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Supporting passage of H.R.4560 To amend the Public Health Service Act to reauthorize Johanna's Law, and for other purposes.
Supporting passage of H.R.913 the CLINICAL TREATMENT Act.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, Ovarian Cancer Research Fund Alliance had in-house lobbyists. The report was filed on Nov. 4, 2020.
Original Filing: 301225804.xml
Lobbying Issues
Supporting passage of ongoing appropriations for DoD's OCRP within the CDMRP.
Supporting passage of ongoing appropriations for CDC's Johanna's Law and Ovarian Cancer Control Initiative.
Supporting passage of ongoing appropriations for NCI.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Supporting passage of H.R.4560 To amend the Public Health Service Act to reauthorize Johanna's Law, and for other purposes.
Supporting passage of H.R.913 the CLINICAL TREATMENT Act.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
In Q2, Ovarian Cancer Research Fund Alliance had in-house lobbyists. The report was filed on Aug. 4, 2020.
Original Filing: 301204525.xml
Lobbying Issues
Supporting passage of ongoing appropriations for DoD's OCRP within the CDMRP.
Supporting passage of ongoing appropriations for CDC's Johanna's Law and Ovarian Cancer Control Initiative.
Supporting passage of ongoing appropriations for NCI.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Supporting passage of H.R.4560 To amend the Public Health Service Act to reauthorize Johanna's Law, and for other purposes.
Supporting passage of H.R.913 the CLINICAL TREATMENT Act.
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, Ovarian Cancer Research Fund Alliance had in-house lobbyists. The report was filed on May 5, 2020.
Original Filing: 301182165.xml
Lobbying Issues
Supporting passage of ongoing appropriations for DoD's OCRP within the CDMRP.
Supporting passage of ongoing appropriations for CDC's Johanna's Law and Ovarian Cancer Control Initiative.
Supporting passage of ongoing appropriations for NCI.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Supporting passage of H.R.4560 To amend the Public Health Service Act to reauthorize Johanna's Law, and for other purposes.
Supporting passage of H.R.913 the CLINICAL TREATMENT Act.
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, Ovarian Cancer Research Fund Alliance had in-house lobbyists. The report was filed on Feb. 20, 2020.
Original Filing: 301142035.xml
Lobbying Issues
Supporting passage of ongoing appropriations for DoD's OCRP within the CDMRP.
Supporting passage of ongoing appropriations for CDC's Johanna's Law and Ovarian Cancer Control Initiative.
Supporting passage of ongoing appropriations for NCI.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Supporting passage of H.R.4560 To amend the Public Health Service Act to reauthorize Johanna's Law, and for other purposes.
Supporting passage of H.R.913 the CLINICAL TREATMENT Act.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, Ovarian Cancer Research Fund Alliance had in-house lobbyists. The report was filed on Nov. 19, 2019.
Original Filing: 301091418.xml
Lobbying Issues
Supporting passage of ongoing appropriations for DoD's OCRP within the CDMRP.
Supporting passage of ongoing appropriations for CDC's Johanna's Law and Ovarian Cancer Control Initiative.
Supporting passage of ongoing appropriations for NCI.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Supporting passage of H.R.4560 To amend the Public Health Service Act to reauthorize Johanna's Law, and for other purposes.
Supporting passage of H.R.913 the CLINICAL TREATMENT Act.
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
In Q1, Ovarian Cancer Research Fund Alliance had in-house lobbyists. The report was filed on April 22, 2019.
Original Filing: 301036965.xml
Lobbying Issues
Supporting increased funding for CDMRP's OCRP in FY2020 Defense appropriations
Support for increased funding fro ovarian cancer reserach and surveillance in FY2020 Labor-HHS-Ed appropriations (no bill # yet)
Supporting the introduction of Access to Genetic Counselor Services Act
Pursuing additional cosponasors and hearing for Cancer Drug Parity Act of 2019 (S.741/H.R.1730)
Pursuing support for CLINICAL TREATMENT Act (H.R.913)
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, Ovarian Cancer Research Fund Alliance had in-house lobbyists. The report was filed on Jan. 22, 2019.
Original Filing: 301016141.xml
Lobbying Issues
FY19 Appropriations for NIH, CDC, and DoD ovarian cancer programs. Supporting H.R.1409 - Cancer Drug Parity Act of 2017. Supporting the re-authorization of Johanna's Law.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, Ovarian Cancer Research Fund Alliance had in-house lobbyists. The report was filed on Nov. 28, 2018.
Original Filing: 301000952.xml
Lobbying Issues
FY19 Appropriations for NIH, CDC, and DoD ovarian cancer programs. Supporting H.R.1409 - Cancer Drug Parity Act of 2017. Supporting the re-authorization of Johanna's Law.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
In Q2, Ovarian Cancer Research Fund Alliance had in-house lobbyists. The report was filed on July 20, 2018.
Original Filing: 300977388.xml
Lobbying Issues
FY19 Appropriations for NIH, CDC, and DoD ovarian cancer programs. Supporting H.R.1409 - Cancer Drug Parity Act of 2017. Supporting the re-authorization of Johanna's Law.
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, Ovarian Cancer Research Fund Alliance had in-house lobbyists. The report was filed on April 20, 2018.
Original Filing: 300953882.xml
Lobbying Issues
FY18 and FY19 Appropriations for NIH, CDC, and DoD ovarian cancer programs. Supporting H.R.1409 - Cancer Drug Parity Act of 2017. Supporting the re-authorization of Johanna's Law.
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
In Q4, Ovarian Cancer Research Fund Alliance had in-house lobbyists. The report was filed on Jan. 24, 2018.
Original Filing: 300938324.xml
Lobbying Issues
FY17 and FY18 Appropriations for NIH, CDC, and DoD ovarian cancer programs. Supporting H.R.1409 - Cancer Drug Parity Act of 2017.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2017
In Q3, Ovarian Cancer Research Fund Alliance had in-house lobbyists. The report was filed on Jan. 24, 2018.
Original Filing: 300938323.xml
Lobbying Issues
FY17 and FY18 Appropriations for NIH, CDC, and DoD ovarian cancer programs. Supporting H.R.1409 - Cancer Drug Parity Act of 2017.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2017
In Q2, Ovarian Cancer Research Fund Alliance had in-house lobbyists. The report was filed on July 20, 2017.
Original Filing: 300896026.xml
Lobbying Issues
FY17 and FY18 Appropriations for NIH, CDC, and DoD ovarian cancer programs. Supporting H.R.1409 - Cancer Drug Parity Act of 2017.
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
In Q1, Ovarian Cancer Research Fund Alliance had in-house lobbyists. The report was filed on April 20, 2017.
Original Filing: 300873552.xml
Lobbying Issues
FY17 and FY18 Appropriations for NIH, CDC, and DoD ovarian cancer programs. Supporting H.R.1409 - Cancer Drug Parity Act of 2017.
Agencies Lobbied
U.S. Senate
4th Quarter, 2016
In Q4, Ovarian Cancer Research Fund Alliance had in-house lobbyists. The report was filed on April 20, 2017.
Original Filing: 300873485.xml
Lobbying Issues
Appropriations for NCI, CDC Ovarian Cancer Programs, OCRP at CDMRP, Regulations for Laboratory Developed Tests, passage of Cancer Drug Parity Act HR 2739/S 1566.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, Ovarian Cancer Research Fund Alliance had in-house lobbyists. The report was filed on Oct. 12, 2016.
Original Filing: 300826776.xml
Lobbying Issues
Appropriations for NCI, CDC Ovarian Cancer Programs, OCRP at CDMRP, Regulations for Laboratory Developed Tests, passage of Cancer Drug Parity Act HR 2739/S 1566.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2016
In Q2, Ovarian Cancer Research Fund Alliance had in-house lobbyists. The report was filed on Oct. 12, 2016.
Original Filing: 300826775.xml
Lobbying Issues
Appropriations for NCI, CDC Ovarian Cancer Programs, OCRP at CDMRP, Regulations for Laboratory Developed Tests, passage of Cancer Drug Parity Act HR 2739/S 1566.
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
In Q1, Ovarian Cancer Research Fund Alliance had in-house lobbyists. The report was filed on Oct. 12, 2016.
Original Filing: 300826774.xml
Lobbying Issues
Appropriations for NCI, CDC Ovarian Cancer Programs, OCRP at CDMRP, Regulations for Laboratory Developed Tests, passage of Cancer Drug Parity Act HR 2739/S 1566.
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
Ovarian Cancer Research Fund Alliance filed a lobbying registration on Feb. 25, 2016 for in-house lobbying efforts, effective Jan. 14, 2016.
Original Filing: 300786986.xml
Issue(s) they said they’d lobby about: Appropriations for National Cancer Institute; CDC Ovarian Cancer Programs; Congressionally Directed Medical Research Program for Ovarian Cancer; 21st Century Cures; Regulation of Laboratory Developed Tests; Preserving Employee Wellness Program Act (S. 620/H.R.1189). .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...